Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSM Insmed	$127.80 +0.0%	$103.62	$60.40 ▼ $128.48	$27.00B	0.95	2.93 million shs	3.53 million shs
RVMD Revolution Medicines	$36.32 +0.8%	$37.93	$29.17 ▼ $62.40	$6.73B	1.16	1.89 million shs	1.39 million shs
SMMT Summit Therapeutics	$26.69 +0.9%	$24.49	$11.29 ▼ $36.91	$19.65B	-1.06	2.73 million shs	2.59 million shs
TEVA Teva Pharmaceutical Industries	$17.86 +1.8%	$16.69	$12.47 ▼ $22.80	$20.12B	0.62	12.74 million shs	8.34 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSM Insmed	+0.04%	+16.66%	+22.19%	+87.61%	+70.70%
RVMD Revolution Medicines	+0.83%	+3.77%	-5.42%	-8.14%	-14.70%
SMMT Summit Therapeutics	+0.91%	-6.87%	-5.59%	+11.81%	+140.02%
TEVA Teva Pharmaceutical Industries	+1.75%	+9.30%	+11.52%	+5.38%	-0.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INSM Insmed	4.1191 of 5 stars	2.5	4.0	0.0	4.3	3.8	1.7	0.6
RVMD Revolution Medicines	4.171 of 5 stars	4.5	1.0	0.0	4.7	1.9	1.7	0.0
SMMT Summit Therapeutics	2.5611 of 5 stars	4.4	1.0	0.0	0.0	2.3	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.8775 of 5 stars	3.6	4.0	0.8	0.0	3.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INSM Insmed	2.94	Moderate Buy	$129.57	1.39% Upside
RVMD Revolution Medicines	3.00	Buy	$68.67	89.06% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$35.00	31.14% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	38.38% Upside

Current Analyst Ratings Breakdown

Latest RVMD, INSM, SMMT, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	RVMD Revolution Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$67.00
8/15/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
8/14/2025	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$126.00 ➝ $139.00
8/14/2025	INSM Insmed	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$121.00 ➝ $145.00
8/13/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$114.00 ➝ $142.00
8/13/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$126.00
8/13/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$129.00 ➝ $148.00
8/13/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $165.00
8/12/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $140.00
8/12/2025	SMMT Summit Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $34.00
8/8/2025	INSM Insmed	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$124.00 ➝ $133.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INSM Insmed	$363.71M	74.27	N/A	N/A	$5.91 per share	21.62
RVMD Revolution Medicines	$11.58M	586.30	N/A	N/A	$9.98 per share	3.64
SMMT Summit Therapeutics	$700K	28,323.81	N/A	N/A	$0.35 per share	76.26
TEVA Teva Pharmaceutical Industries	$16.63B	1.23	$3.43 per share	5.21	$5.96 per share	3.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INSM Insmed	-$913.77M	-$5.71	N/A	N/A	N/A	-259.82%	-195.37%	-49.49%	10/30/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.50	N/A	N/A	N/A	N/A	-41.78%	-35.63%	N/A
SMMT Summit Therapeutics	-$221.32M	-$1.01	N/A	N/A	N/A	N/A	-208.64%	-181.28%	10/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	6.79	1.04	-0.95%	46.10%	7.18%	N/A

Latest RVMD, INSM, SMMT, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	-$0.76	-$0.66	-$0.76	N/A	N/A
8/7/2025	Q2 2025	INSM Insmed	-$1.30	-$1.70	-$0.40	-$1.70	$104.06 million	$107.42 million
8/6/2025	Q2 2025	RVMD Revolution Medicines	-$0.94	-$1.31	-$0.37	-$1.31	$0.50 million	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INSM Insmed	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.66%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INSM Insmed	0.45	6.68	6.33
RVMD Revolution Medicines	0.13	11.79	11.79
SMMT Summit Therapeutics	N/A	5.13	10.63
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INSM Insmed	N/A
RVMD Revolution Medicines	94.34%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
INSM Insmed	3.00%
RVMD Revolution Medicines	8.20%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INSM Insmed	1,271	211.38 million	205.03 million	Optionable
RVMD Revolution Medicines	250	186.93 million	171.60 million	Optionable
SMMT Summit Therapeutics	110	742.85 million	112.17 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

RVMD, INSM, SMMT, and TEVA Headlines

Recent News About These Companies

Public Sector Pension Investment Board Has $9.03 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 16 at 4:43 AM | marketbeat.com

Virtu Financial LLC Buys Shares of 24,154 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 16 at 4:19 AM | marketbeat.com

Deutsche Bank AG Boosts Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 14 at 4:00 AM | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 53,443 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 13 at 4:05 AM | marketbeat.com

Senores Pharma to acquire two products of USFDA approved ANDAs from Teva Pharma USA

August 13 at 3:07 AM | medicaldialogues.inM

Teva Pharmaceutical continues gains for seven straight sessions

August 12, 2025 | msn.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by Todd Asset Management LLC

August 12, 2025 | marketbeat.com

30,900 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Purchased by ASR Vermogensbeheer N.V.

August 11, 2025 | marketbeat.com

Headlands Technologies LLC Has $486,000 Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 10, 2025 | marketbeat.com

Keystone Investors PTE Ltd. Acquires Shares of 45,432 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 9, 2025 | marketbeat.com

iA Global Asset Management Inc. Reduces Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 7, 2025 | marketbeat.com

Teva’s Ajovy becomes first migraine prevention drug approved for children

August 6, 2025 | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Sells $91,763.48 in Stock

August 6, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Eric A. Hughes Sells 52,742 Shares

August 6, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Sells $91,763.48 in Stock

August 6, 2025 | insidertrades.com

Natixis Advisors LLC Has $5.12 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 6, 2025 | marketbeat.com

US FDA approves Teva's Ajovy for migraine prevention in children

August 5, 2025 | reuters.com

TD Asset Management Inc Has $3.62 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by King Wealth Management Group

August 1, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Buy" by Analysts

August 1, 2025 | marketbeat.com

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

July 31, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD, INSM, SMMT, and TEVA Company Descriptions

Insmed NASDAQ:INSM

$127.80 +0.05 (+0.04%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$127.19 -0.61 (-0.47%)

As of 08/15/2025 07:56 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Revolution Medicines NASDAQ:RVMD

$36.32 +0.30 (+0.83%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$36.32 0.00 (0.00%)

As of 08/15/2025 04:34 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Summit Therapeutics NASDAQ:SMMT

$26.69 +0.24 (+0.91%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$26.60 -0.10 (-0.36%)

As of 08/15/2025 07:55 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$17.86 +0.32 (+1.82%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$17.92 +0.07 (+0.36%)

As of 08/15/2025 07:59 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time